Modeling-Based response-guided glecaprevir-pibrentasvir therapy for chronic hepatitis C to identify patients for ultrashort treatment duration

Swikriti Dasgupta; Michio Imamura; Evan Gorstein; Takashi Nakahara; Masataka Tsuge; Alexander Churkin; David Yardeni; Ohad Etzion; Susan L. Uprichard; Danny Barash; Scott J. Cotler; Harel Dahari; Kazuaki Chayama

doi:10.1093/infdis/jiaa219

Modeling-Based response-guided glecaprevir-pibrentasvir therapy for chronic hepatitis C to identify patients for ultrashort treatment duration

Swikriti Dasgupta, Michio Imamura, Evan Gorstein, Takashi Nakahara, Masataka Tsuge, Alexander Churkin, David Yardeni, Ohad Etzion, Susan L. Uprichard, Danny Barash, Scott J. Cotler, Harel Dahari, Kazuaki Chayama

Department of Computer Science

Ben-Gurion University of the Negev

Research output: Contribution to journal › Article › peer-review

Abstract

We recently showed in a proof-of-concept study that real-time modeling-based response-guided therapy can shorten hepatitis C virus treatment duration with sofosbuvir-velpatasvir, elbasvir-grazoprevir, and sofosbuvir-ledipasvir without compromising efficacy, confirming our retrospective modeling reports in >200 patients. However, retrospective modeling of pibrentasvir-glecaprevir (P/G) treatment has yet to be evaluated. In the current study, modeling hepatitis C virus kinetics in 44 cirrhotic and noncirrhotic patients predicts that P/G treatment might have been reduced to 4, 6, and 7 weeks in 16%, 34%, and 14% of patients, respectively. These results support the further evaluation of a modeling-based response-guided therapy approach using P/G.

Original language	American English
Pages (from-to)	1165-1169
Number of pages	5
Journal	Journal of Infectious Diseases
Volume	222
Issue number	7
DOIs	https://doi.org/10.1093/infdis/jiaa219
State	Published - 1 Oct 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Direct-acting antivirals
Hepatitis C virus
Mathematical modeling
Response-guided therapy

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Infectious Diseases

Access to Document

10.1093/infdis/jiaa219

Cite this

Dasgupta, S., Imamura, M., Gorstein, E., Nakahara, T., Tsuge, M., Churkin, A., Yardeni, D., Etzion, O., Uprichard, S. L., Barash, D., Cotler, S. J., Dahari, H., & Chayama, K. (2020). Modeling-Based response-guided glecaprevir-pibrentasvir therapy for chronic hepatitis C to identify patients for ultrashort treatment duration. Journal of Infectious Diseases, 222(7), 1165-1169. https://doi.org/10.1093/infdis/jiaa219

@article{2f086d7787244eb5bacdffb13f38de7a,

title = "Modeling-Based response-guided glecaprevir-pibrentasvir therapy for chronic hepatitis C to identify patients for ultrashort treatment duration",

abstract = "We recently showed in a proof-of-concept study that real-time modeling-based response-guided therapy can shorten hepatitis C virus treatment duration with sofosbuvir-velpatasvir, elbasvir-grazoprevir, and sofosbuvir-ledipasvir without compromising efficacy, confirming our retrospective modeling reports in >200 patients. However, retrospective modeling of pibrentasvir-glecaprevir (P/G) treatment has yet to be evaluated. In the current study, modeling hepatitis C virus kinetics in 44 cirrhotic and noncirrhotic patients predicts that P/G treatment might have been reduced to 4, 6, and 7 weeks in 16%, 34%, and 14% of patients, respectively. These results support the further evaluation of a modeling-based response-guided therapy approach using P/G.",

keywords = "Direct-acting antivirals, Hepatitis C virus, Mathematical modeling, Response-guided therapy",

author = "Swikriti Dasgupta and Michio Imamura and Evan Gorstein and Takashi Nakahara and Masataka Tsuge and Alexander Churkin and David Yardeni and Ohad Etzion and Uprichard, {Susan L.} and Danny Barash and Cotler, {Scott J.} and Harel Dahari and Kazuaki Chayama",

year = "2020",

month = oct,

day = "1",

doi = "10.1093/infdis/jiaa219",

language = "American English",

volume = "222",

pages = "1165--1169",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "7",

}

Dasgupta, S, Imamura, M, Gorstein, E, Nakahara, T, Tsuge, M, Churkin, A, Yardeni, D, Etzion, O, Uprichard, SL, Barash, D, Cotler, SJ, Dahari, H & Chayama, K 2020, 'Modeling-Based response-guided glecaprevir-pibrentasvir therapy for chronic hepatitis C to identify patients for ultrashort treatment duration', Journal of Infectious Diseases, vol. 222, no. 7, pp. 1165-1169. https://doi.org/10.1093/infdis/jiaa219

TY - JOUR

T1 - Modeling-Based response-guided glecaprevir-pibrentasvir therapy for chronic hepatitis C to identify patients for ultrashort treatment duration

AU - Dasgupta, Swikriti

AU - Imamura, Michio

AU - Gorstein, Evan

AU - Nakahara, Takashi

AU - Tsuge, Masataka

AU - Churkin, Alexander

AU - Yardeni, David

AU - Etzion, Ohad

AU - Uprichard, Susan L.

AU - Barash, Danny

AU - Cotler, Scott J.

AU - Dahari, Harel

AU - Chayama, Kazuaki

PY - 2020/10/1

Y1 - 2020/10/1

N2 - We recently showed in a proof-of-concept study that real-time modeling-based response-guided therapy can shorten hepatitis C virus treatment duration with sofosbuvir-velpatasvir, elbasvir-grazoprevir, and sofosbuvir-ledipasvir without compromising efficacy, confirming our retrospective modeling reports in >200 patients. However, retrospective modeling of pibrentasvir-glecaprevir (P/G) treatment has yet to be evaluated. In the current study, modeling hepatitis C virus kinetics in 44 cirrhotic and noncirrhotic patients predicts that P/G treatment might have been reduced to 4, 6, and 7 weeks in 16%, 34%, and 14% of patients, respectively. These results support the further evaluation of a modeling-based response-guided therapy approach using P/G.

AB - We recently showed in a proof-of-concept study that real-time modeling-based response-guided therapy can shorten hepatitis C virus treatment duration with sofosbuvir-velpatasvir, elbasvir-grazoprevir, and sofosbuvir-ledipasvir without compromising efficacy, confirming our retrospective modeling reports in >200 patients. However, retrospective modeling of pibrentasvir-glecaprevir (P/G) treatment has yet to be evaluated. In the current study, modeling hepatitis C virus kinetics in 44 cirrhotic and noncirrhotic patients predicts that P/G treatment might have been reduced to 4, 6, and 7 weeks in 16%, 34%, and 14% of patients, respectively. These results support the further evaluation of a modeling-based response-guided therapy approach using P/G.

KW - Direct-acting antivirals

KW - Hepatitis C virus

KW - Mathematical modeling

KW - Response-guided therapy

UR - http://www.scopus.com/inward/record.url?scp=85087493478&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiaa219

DO - 10.1093/infdis/jiaa219

M3 - Article

C2 - 32363394

SN - 0022-1899

VL - 222

SP - 1165

EP - 1169

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 7

ER -

Modeling-Based response-guided glecaprevir-pibrentasvir therapy for chronic hepatitis C to identify patients for ultrashort treatment duration

Abstract

UN SDGs

Keywords

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this